Predicting the outcome of ankylosing spondylitis therapy

Predicting the outcome of ankylosing spondylitis therapy

Objectives To create a model that provides a potential basis for candidate selection for anti-tumour necrosis factor (TNF) treatment by predicting future outcomes relative to the current disease profile of individual patients with ankylosing spondylitis (AS). Methods ASSERT and GO–RAISE trial data (...

Whakaahuatanga katoa

I tiakina i:

Ngā taipitopito rārangi puna kōrero
Ngā kaituhi matua:	Nathan Vastesaeger, Désirée van der Heijde, Robert D. Inman, Yanxin Wang, Atul Deodhar, Benjamin Hsu, Mahboob U. Rahman, Ben A. C. Dijkmans, Piet Geusens, Bert Vander Cruyssen, Eduardo Collantes‐Estévez, Joachim Sieper, Jürgen Braun
Hōputu:	Artigo
Reo:	Ingarihi
I whakaputaina:	2011
Urunga tuihono:	https://doi.org/10.1136/ard.2010.147744 https://ard.bmj.com/content/annrheumdis/70/6/973.full.pdf
Ngā Tūtohu:	Tāpirihia he Tūtohu Kāore He Tūtohu, Me noho koe te mea tuatahi ki te tūtohu i tēnei pūkete!

Ngā tūemi rite

Predicting the outcome of ankylosing spondylitis therapy
mā: Vastesaeger, Nathan, me ētahi atu.
I whakaputaina: (2011)

Hip involvement in ankylosing spondylitis: epidemiology and risk factors associated with hip replacement surgery
mā: Bert Vander Cruyssen, me ētahi atu.
I whakaputaina: (2009)

Modified stoke ankylosing spondylitis spinal score as an outcome measure to assess the impact of treatment on structural progression in ankylosing spondylitis
mā: van der Heijde, Désirée, me ētahi atu.
I whakaputaina: (2019)

Modified stoke ankylosing spondylitis spinal score as an outcome measure to assess the impact of treatment on structural progression in ankylosing spondylitis
mā: Désirée van der Heijde, me ētahi atu.
I whakaputaina: (2018)

Golimumab administered subcutaneously every 4 weeks in ankylosing spondylitis: 104-week results of the GO-RAISE study
mā: Braun, Jürgen, me ētahi atu.
I whakaputaina: (2011)

Golimumab administered subcutaneously every 4 weeks in ankylosing spondylitis: 104-week results of the GO-RAISE study
mā: Jürgen Braun, me ētahi atu.
I whakaputaina: (2011)

Serum markers associated with clinical improvement in patients with ankylosing spondylitis treated with golimumab
mā: Wagner, Carrie, me ētahi atu.
I whakaputaina: (2011)

Ankylosing spondylitis: an overview
mā: Joachim Sieper, me ētahi atu.
I whakaputaina: (2002)

Golimumab administered subcutaneously every 4 weeks in ankylosing spondylitis: 5-year results of the GO-RAISE study
mā: Deodhar, Atul, me ētahi atu.
I whakaputaina: (2015)

Golimumab administered subcutaneously every 4 weeks in ankylosing spondylitis: 5-year results of the GO-RAISE study
mā: Atul Deodhar, me ētahi atu.
I whakaputaina: (2014)

Anti-tumour necrosis factor α therapy for ankylosing spondylitis: international experience
mā: Braun, J, me ētahi atu.
I whakaputaina: (2002)

The Effect of Golimumab Therapy on Disease Activity and Health-related Quality of Life in Patients with Ankylosing Spondylitis: 2-year Results of the GO-RAISE Trial
mā: Désirée van der Heijde, me ētahi atu.
I whakaputaina: (2014)

Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis
mā: Dominique Baeten, me ētahi atu.
I whakaputaina: (2015)

First update of the international ASAS consensus statement for the use of anti-TNF agents in patients with ankylosing spondylitis
mā: Jürgen Braun, me ētahi atu.
I whakaputaina: (2005)

Golimumab reduces spinal inflammation in ankylosing spondylitis: MRI results of the randomised, placebo- controlled GO-RAISE study
mā: Jürgen Braun, me ētahi atu.
I whakaputaina: (2011)

Fifty years after the discovery of the association of HLA B27 with ankylosing spondylitis
mā: Jürgen Braun, me ētahi atu.
I whakaputaina: (2023)

Serum biomarkers and changes in clinical/MRI evidence of golimumab-treated patients with ankylosing spondylitis: results of the randomized, placebo-controlled GO-RAISE study
mā: Inman, Robert D., me ētahi atu.
I whakaputaina: (2016)

Efficacy and safety of upadacitinib in patients with ankylosing spondylitis refractory to biologic therapy: 1-year results from the open-label extension of a phase III study
mā: Xenofon Baraliakos, me ētahi atu.
I whakaputaina: (2023)

The effect of two golimumab doses on radiographic progression in ankylosing spondylitis: results through 4 years of the GO-RAISE trial
mā: Braun, Jürgen, me ētahi atu.
I whakaputaina: (2014)

The effect of two golimumab doses on radiographic progression in ankylosing spondylitis: results through 4 years of the GO-RAISE trial
mā: Jürgen Braun, me ētahi atu.
I whakaputaina: (2013)

The epidemiology of ankylosing spondylitis and the commencement of anti‐TNF therapy in daily rheumatology practice
mā: Cruyssen, Bert Vander, me ētahi atu.
I whakaputaina: (2007)

The epidemiology of ankylosing spondylitis and the commencement of anti-TNF therapy in daily rheumatology practice
mā: Bert Vander Cruyssen, me ētahi atu.
I whakaputaina: (2007)

Spinal Radiographic Changes in Ankylosing Spondylitis: Association with Clinical Characteristics and Functional Outcome
mā: Annelies Boonen, me ētahi atu.
I whakaputaina: (2009)

Impact of baseline C-reactive protein levels on the response to secukinumab in ankylosing spondylitis: 3-year pooled data from two phase III studies
mā: Braun, Jürgen, me ētahi atu.
I whakaputaina: (2018)

The epidemiology of osteoporosis and fractures in ankylosing spondylitis
mā: Sambrook, Philip N., me ētahi atu.
I whakaputaina: (2012)

The epidemiology of osteoporosis and fractures in ankylosing spondylitis
mā: Philip N. Sambrook, me ētahi atu.
I whakaputaina: (2012)

Golimumab reduces spinal inflammation in ankylosing spondylitis: MRI results of the randomised, placebo- controlled GO-RAISE study
mā: Braun, Jürgen, me ētahi atu.
I whakaputaina: (2011)

ASAS/EULAR recommendations for the management of ankylosing spondylitis
mā: Zochling, J, me ētahi atu.
I whakaputaina: (2006)

Efficacy and safety of upadacitinib for active ankylosing spondylitis refractory to biological therapy: a double-blind, randomised, placebo-controlled phase 3 trial
mā: Désirée van der Heijde, me ētahi atu.
I whakaputaina: (2022)

Etanercept in the Longterm Treatment of Patients With Ankylosing Spondylitis
mā: Ben A. C. Dijkmans, me ētahi atu.
I whakaputaina: (2009)

Ankylosing spondylitis: an overview
mā: Sieper, J, me ētahi atu.
I whakaputaina: (2002)

Effects of infliximab on markers of inflammation and bone turnover and associations with bone mineral density in patients with ankylosing spondylitis
mā: Sudha Visvanathan, me ētahi atu.
I whakaputaina: (2008)

2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis
mā: Braun, J, me ētahi atu.
I whakaputaina: (2011)

Therapy of ankylosing spondylitis and other spondyloarthritides: established medical treatment, anti-TNF-alpha therapy and other novel approaches.
mā: Jürgen Braun, me ētahi atu.
I whakaputaina: (2002)

Definition of disease duration in ankylosing spondylitis: reassessing the concept
mā: Davis, J C, me ētahi atu.
I whakaputaina: (2006)

Adalimumab effectively reduces the signs and symptoms of active ankylosing spondylitis in patients with total spinal ankylosis
mā: Désirée van der Heijde, me ētahi atu.
I whakaputaina: (2007)

Staging of patients with ankylosing spondylitis: a preliminary proposal
mā: Braun, J, me ētahi atu.
I whakaputaina: (2002)

Adalimumab effectiveness for the treatment of ankylosing spondylitis is maintained for up to 2 years: long-term results from the ATLAS trial
mā: Désirée van der Heijde, me ētahi atu.
I whakaputaina: (2008)

Determinants of hyperkyphosis in patients with ankylosing spondylitis
mā: Vosse, D, me ētahi atu.
I whakaputaina: (2006)

Effect of secukinumab on clinical and radiographic outcomes in ankylosing spondylitis: 2-year results from the randomised phase III MEASURE 1 study
mā: Jürgen Braun, me ētahi atu.
I whakaputaina: (2016)